Brain imaging characteristics of MOG antibody disease are largely unknown and it is unclear whether they differ from those of multiple sclerosis and AQP4 antibody disease. The aim of this study was to identify brain imaging discriminators between those three inflammatory central nervous system diseases in adults and children to support diagnostic decisions, drive antibody testing and generate disease mechanism hypotheses. Clinical brain scans of 83 patients with brain lesions (67 in the training and 16 in the validation cohort, 65 adults and 18 children) with MOG antibody (n = 26), AQP4 antibody disease (n = 26) and multiple sclerosis (n = 31) recruited from Oxford neuromyelitis optica and multiple sclerosis clinical services were retrospectively and anonymously scored on a set of 29 predefined magnetic resonance imaging features by two independent raters. Principal component analysis was used to perform an overview of patients without a priori knowledge of the diagnosis. Orthogonal partial least squares discriminant analysis was used to build models separating diagnostic groups and identify best classifiers, which were then tested on an independent cohort set. Adults and children with MOG antibody disease frequently had fluffy brainstem lesions, often located in pons and/or adjacent to fourth ventricle. Children across all conditions showed more frequent bilateral, large, brainstem and deep grey matter lesions. MOG antibody disease spontaneously separated from multiple sclerosis but overlapped with AQP4 antibody disease. Multiple sclerosis was discriminated from MOG antibody disease and from AQP4 antibody disease with high predictive values, while MOG antibody disease could not be accurately discriminated from AQP4 antibody disease. Best classifiers between MOG antibody disease and multiple sclerosis were similar in adults and children, and included ovoid lesions adjacent to the body of lateral ventricles, Dawson's fingers, T 1 hypointense lesions (multiple sclerosis), fluffy lesions and three lesions or less (MOG antibody). In the validation cohort patients with antibody-mediated conditions were differentiated from multiple sclerosis with high accuracy. Both antibody-mediated conditions can be clearly separated from multiple sclerosis on conventional brain imaging, both in adults and children. The overlap between MOG antibody oligodendrocytopathy and AQP4 antibody astrocytopathy suggests that the primary immune target is not the main substrate for brain lesion characteristics. This is also supported by the clear distinction between multiple sclerosis and MOG antibody disease both considered primary demyelinating conditions. We identify discriminatory features, which may be useful in classifying atypical multiple sclerosis, seronegative neuromyelitis optica spectrum disorders and relapsing acute disseminated encephalomyelitis, and characterizing cohorts for antibody discovery. Correspondence may also be addressed to: Maciej Jurynczyk. E-mail: maciej.jurynczyk@ndcn.ox.ac.uk Keywords: multiple sclerosis; neuromyelitis optica; autoantibodies; magnetic resonance imaging Abbreviations: ADEM = acute disseminated encephalomyelitis; NMOSD = neuromyelitis optica spectrum disorders; OPLS-DA = orthogonal partial least squares discriminant analysis; PCA = principal component analysis
Introduction
Myelin oligodendrocyte glycoprotein (MOG) is a CNS-specific protein, which due to its location in the outer layers of the myelin sheath, is a good candidate for autoimmune demyelination (Brunner et al., 1989) . Autoimmunity against MOG has been historically linked with multiple sclerosis and its animal models (Schluesener et al., 1987; Linington et al., 1988) . Studies using traditional antibody detecting methods such as ELISA and western blot identified MOG antibodies predominantly in the serum of patients with multiple sclerosis but also in other types of CNS inflammation and in healthy controls (Xiao et al., 1991; Bernard et al., 1997; Reindl et al., 1999; Haase and Schmidt, 2001; Zhou et al., 2006; Wang et al., 2008) . The recent development of assays using soluble, tetramerized extracellular domain of native MOG, and particularly refined cell-based techniques, have demonstrated that antibodies to conformationally intact extracellular MOG are highly specific for a subgroup of patients with acute disseminated encephalomyelitis (ADEM) and AQP4 antibody-negative neuromyelitis optica spectrum disorders (NMOSD) (O'Connor et al., 2007; Kitley et al., 2012 Kitley et al., , 2014 Sato et al., 2014; Baumann et al., 2015; Waters et al., 2015) . These findings led to the concept that MOG antibodies define a new clinical entity distinct from multiple sclerosis and AQP4 antibody-positive NMOSD. This view is supported by limited evidence that MOG antibodies cause oligodendrocyte damage and primary demyelination in vitro and in vivo (von Bü dingen et al., 2002; Marta et al., 2005 Marta et al., , 2008 Dale et al., 2014; Ikeda et al., 2015) and that there are unique and sterotypical features of MOG antibody-associated syndromes (Kitley et al., 2012 (Kitley et al., , 2014 Sato et al., 2014; Baumann et al., 2015) . Although initially reported as a monophasic condition (Kitley et al., 2012 (Kitley et al., , 2014 , it appears to be relapsing in $50% of cases (Sato et al., 2014) and can be difficult to distinguish from multiple sclerosis and AQP4 antibody NMOSD. In addition, a specific MOG antibody assay is not widely available. On the other hand AQP4 antibody disease is regarded as an astrocytopathy, which is always relapsing with a worse prognosis (Wingerchuk et al., 2007) . There are distinct gender and age demographics between the three conditions and importantly the treatment regimens differ in case of multiple sclerosis and AQP4 antibody NMOSD, and are not fully established for MOG antibody disease.
To explore the distinction of MOG antibody-associated disease from its mimics, multiple sclerosis and AQP4 antibody NMOSD, we studied, using conventional brain MRI, adults and children with brain lesions to build diagnostic algorithms. We also wished to assess the imaging features of MOG antibody disease in a larger population than previously described. It was of interest to assess whether the disease target or mechanism would drive the imaging features.
Materials and methods

Patients
Patients were recruited through the Oxford neuromyelitis optica (NMO) or multiple sclerosis clinics (Oxford Research Ethics Committee C Ref: 10/H0606/56). Only patients with brain MRI lesions were included in the study.
Patient selection
For the training set we screened all MOG antibody patients seen in our NMO clinic between June 2010 and September 2015 (n = 36) and recruited only those with brain lesions (n = 21, i.e. 58%). For the subsequent validation study we screened all MOG antibody patients seen between September 2015 and May 2016 (n = 9) and again included only those with brain lesions (n = 5, i.e. 56%). We selected consecutive most recently seen AQP4 antibody patients (from September 2015 back) to reach a similar number of patients with brain lesions (20/29, i.e. 69%) and again from May 2016 back for the validation study (6/10, i.e. 60%). The patients with multiple sclerosis were consecutively recruited from first visit multiple sclerosis disease-modifying therapy clinic (from September 2015 back for the training study, n = 21, and from May 2016 back for the validation study, n = 5) if they had brain MRI scans available at onset. For the paediatric cohort we included all the children with multiple sclerosis (n = 5) known to the service because of the small numbers in our clinical service.
Brain scans and scoring
Earliest available clinical brain MRI scans showing brain lesions (typically at relapse) were selected for each patient and transferred from PACS (Picture Archiving and Communication System) to ClearCanvas (Synaptive Medical). Dicom files were downloaded, anonymized and converted to Nifti files. Images were blindly assessed and scored according to the location, number and characteristics of lesions by two independent raters (M.J., R.G.) using FSLview (FMRIB Software Library v5.0, University of Oxford). The characteristics scored incorporated features reported to be specific for multiple sclerosis and NMOSD (Table 1) . Diffuse splenium lesions were defined as T 2 hyperintense lesions spreading bilaterally within the splenium of corpus callosum (Makino et al., 2013) . Lesions were scored as large if their size exceeded 2 cm in any plane. Lesions were considered fluffy if they were poorly demarcated. The patient was scored positive on fluffy lesions or any other feature if they had at least one lesion in keeping with this characteristic. In case of disagreement a final consensus was reached between raters supported by neuroradiology reports. After scoring had been finished scans were decoded and patients were grouped according to the diagnosis and age group (children 5 18 years, adult 4 18 years).
Testing for MOG IgG1 and AQP4 IgG antibodies
Serum samples from all patients recruited from NMO clinic were tested for the presence of MOG IgG1 and AQP4 IgG antibodies by cell-based assays as described previously (Waters et al., , 2015 . All MOG antibody patients were negative for AQP4 antibodies and vice versa. All multiple sclerosis children were negative for both MOG and AQP4 antibodies. Adult multiple sclerosis patients were not routinely tested for antibodies as our earlier research showed that the optimized cell-based assays are specific for non-multiple sclerosis disease (Waters et al., , 2015 . 
Inter-rater agreement
Cohen's kappa () was used to assess inter-rater agreement. A 5 0 indicates poor agreement, 0.01-0.20 slight, 0.21-0.40 fair, 0.41-0.60 moderate, 0.61-0.80 substantial and 0.81-1.0 almost perfect agreement. To represent overall agreement we calculated mean from values obtained for each patient. We also measured for each individual MRI feature.
Multivariate statistical analysis
Principal component analysis (PCA) summarizes multiple variables across individual patients without including the diagnosis in the model. PCA was thus used to separate patients on the basis of MRI features without a priori knowledge of the diagnosis.
Orthogonal partial least squares discriminant analysis (OPLS-DA) is a regression and prediction method used when working with discrete variables (e.g. diagnostic groups) to identify variables responsible for class discrimination (Trygg and Wold, 2002) . OPLS-DA separates the systemic variation in X (MRI features) into two parts, the one that is correlated (predictive) to Y (diagnosis) and the one that is uncorrelated (orthogonal) to Y (i.e. variable within diagnostic groups). Each model was assessed for the total variation in X explained by the model (R2X), the total variation in Y explained by the model (R2Y) and goodness of prediction, calculated by full cross validation (q 2 ). A R2Y of 100% suggests that the model can totally explain the variation in the diagnostic groups and 0% that it cannot explain any difference between the groups. The higher R2Y and q 2 , the better is the separation between diagnostic groups. A q 2 4 0 is predictive and it is generally accepted that q 2 4 0.4 is the threshold for significance in biological modelling (Waterman et al., 2010) . Initially the model was run to separate the patients into their three diagnostic groups and then to best identify diagnostic discriminators, OPLS-DA models were run with each of the three pairs of diagnostic classes at a time (multiple sclerosis versus MOG antibody, multiple sclerosis versus AQP4 antibody, MOG antibody versus AQP4 antibody). Extraction of putative classifiers is represented on S-plots, which visualize OPLS-DA loadings, i.e. the x-axis describes the magnitude of each variable in X and the y-axis represents the reliability of each variable in X. An ideal biomarker has high magnitude and high reliability. For each of the three pairs of comparisons, variables with VIP (Variable Importance for the Projection) values 4 1.5 were considered the best classifiers and the goodness of prediction was calculated when only including those variables. These variables were then used to build OPLS-DA model for all three diseases together. Multivariate statistical analysis and PCA and OPLS-DA plots were done using Simca 14 (MKS Data Analytics Solutions, Sweden). Both methods were used in our previous research for group discrimination using multivariate data (Griffin et al., 2004; Dickens et al., 2015) .
Independent validation
Patients from the validation cohort were assigned to distinct diagnostic groups using previously built discriminatory models. The results were expressed as 2 Â 2 contingency tables. Model membership probability thresholds derived from the modelbuilding set were used to determine accuracy in the prediction set.
Results
The inter-rater agreement was found to be = 0.74 (P 5 0.001), 95% confidence interval (CI) 0. 
Training set
Brain MRI scans of 21 patients with MOG antibody disease (15 adults, six children), 20 patients with AQP4 antibody NMOSD (13 adults, seven children) and 26 patients with multiple sclerosis (21 adults, 5 children) were assessed by raters. The results of scoring and basic demographic data are shown in Table 1 .
MRI brain lesion characteristics in patients with MOG antibody-associated disorder
Lesions in patients with MOG antibody were typically few (53), poorly demarcated (fluffy) and located infratentorially, in the brainstem or cerebellar peduncles and were often adjacent to the fourth ventricle (Table 1 and Fig. 1 ). Other lesions considered to be specific for AQP4 antibody NMOSD, such as adjacent to the third ventricle, periaqueductal or located in area postrema, were also not uncommon in MOG antibody patients.
Seventy per cent of patients with brain lesions had clinically eloquent attacks. For example, clinical NMO could have been associated with clinically silent brainstem lesions. Patients who had brain lesions during an attack were more likely to have a simultaneous transverse myelitis (75%) than optic neuritis (50%). Clinical presentation in all patients from the training and validation cohort is shown in Supplementary Table 2.
In the 76% of patients with MOG antibody disease who had a follow-up brain MRI, all showed complete or near complete resolution of lesions without new lesion development.
Adults versus children
The proportion of bilateral lesions, large lesions, deep grey matter and brainstem lesions (including area postrema lesions) were higher in children than in adults across all three diagnoses (Table 1) .
Children with MOG antibody disease had periventricular, subcortical lesions and lesions involving cortex and lesions adjacent to third ventricle more often than adults with MOG antibody disease (Table 1 ). In the MOG antibody group children had encephalopathy (83% versus 14%) more often than adults, consistent with ADEM.
Overview of individual patients using PCA discounting the diagnosis Using PCA on the brain MRI features we found that patients tended to spontaneously separate into their diagnostic groups (Fig. 2) . Interestingly, patients with MOG antibody disease fully separated from patients with multiple sclerosis, while AQP4 antibody NMOSD patients partially overlapped with both MOG antibody and multiple sclerosis patients (Fig. 2) . Because there were marked differences in the frequency of some MRI features between children and adult MRIs, disease discriminatory models (OPLS-DA) were subsequently applied to these two groups separately.
MRI brain features discriminating between three diseases in adults
To isolate between-group differences in adult patients, we constructed an OPLS-DA model, which separated the three diseases (Fig. 3A , parameters of all models are shown in Supplementary Table 3) . We then built separate models for each pair of diseases to identify the best diagnostic classifiers ( Fig. 3B-D) . The model discriminating MOG antibody disorder from multiple sclerosis had high goodness of prediction (q 2 = 0.78), explaining 86% of the variation in diagnoses (R2Y), confirming distinct characteristics of the two diseases. The multiple sclerosis versus AQP4 antibody model was also predictive (q 2 = 0.43, R2Y 75%), while MOG antibody versus AQP4 antibody was non-predictive suggesting that the two diseases share overlapping characteristics on brain MRI (Supplementary Table 3 ). The best classifiers for each pair of diseases are shown in Fig. 3B -D. For MOG antibody versus multiple sclerosis these included ovoid lesions adjacent to the body of lateral ventricles, Dawson's fingers (both multiple sclerosis), fluffy lesions and three lesions or less (both MOG antibody). Models built with only best classifiers (VIP 4 1.5) had similar or slightly better predictive value to those built with all variables (Supplementary Table 3 ). Because of differences in disease duration between groups we built separate models matching for onset time to MRI and did not find significant differences in best classifiers. Most importantly, the number of lesions was identified as one of the most important classifiers with VIP at 1.5 in both MOG antibody versus multiple sclerosis and AQP4 antibody versus multiple sclerosis models. We did not find any clustering of patients according to gender and when building models only on the female cohort we still observed an overlap of MOG antibody and AQP4 antibody patients and their clear separation from multiple sclerosis ( Supplementary Fig. 1 ) with the same discriminatory features (data not shown).
Because of the overlap between two antibody-mediated conditions we split them in to two conditions: multiple sclerosis and antibody-mediated conditions. We then built a separate model on the training set of patients to differentiate multiple sclerosis from two antibody-mediated conditions combined together (q 2 = 0.69).
MRI brain features discriminating between three diseases in children
The OPLS-DA model separating three diseases in children is shown on Supplementary Fig. 2A . Similarly as in adults, OPLS-DA model separating MOG antibody disease from multiple sclerosis in children showed high goodness of prediction (q 2 = 0.96, R2Y 100%). The AQP4 antibody NMOSD versus multiple sclerosis model was also highly predictive (q 2 = 0.7, R2Y 98%), while the model separating MOG antibody disease from AQP4 antibody disease was non-predictive (Supplementary Table 3 ). The best diagnostic classifiers for each model are shown on Supplementary  Fig. 2B -D and included T 1 hypointense lesions, Dawson's fingers and ovoid lesions adjacent to the body of lateral ventricles (discriminating multiple sclerosis from both antibody-mediated conditions). Smaller plots to the right show separate PCA models for adults (top) and children (bottom). AQP4 = AQP4 antibody disease; MOG-Ab = MOG antibody disease; MS = multiple sclerosis.
Validation set
The validation set included 16 adult patients (five MOG antibody, six AQP4 antibody and five multiple sclerosis).
Patients from this group were tested using the previously built OPLS-DA models (Fig. 4 and Table 2 ). MOG antibody versus multiple sclerosis model classified all patients correctly except one MOG antibody patient who was borderline misclassified as multiple sclerosis with class membership probability at 65% (Fig. 4A and Table 2 ). The accuracy of the model was thus 90%.
The multiple sclerosis versus AQP4 antibody model was also very accurate (91%) with all patients correctly classified apart from one undetermined multiple sclerosis patient (AQP4 antibody membership probability 52%) (Fig. 4B and Table 2 ). As expected, the model differentiating MOG antibody disease from AQP4 antibody did not perform well (accuracy at 64%, Fig. 4C and Table 2 ).
The accuracy of the model discriminating between multiple sclerosis and two antibody-mediated conditions combined together showed accuracy at 94% (Fig. 4D and Table 2 ).
Discussion
In this study using only routine clinical scans obtained on different MRI machines, across different centres, and selecting a set of multiple brain MRI features we have shown that MOG antibody disease, and AQP4 antibody disease display different imaging characteristics from multiple sclerosis, and that these two antibody-mediated diseases can be distinguished from multiple sclerosis with high accuracy. In contrast, MOG antibody and AQP4 antibody diseases overlap despite targeting distinct cell types. These results were confirmed with a further validation cohort. We noted fluffy brainstem lesions in MOG antibody disease, which were not previously highlighted. Children had more frequent bilateral, large, brainstem and deep grey matter lesions in comparison to adults. In addition to childhood multiple sclerosis being associated with more extensive brain MRI changes we show this is a feature across all three inflammatory CNS diseases (Waubant et al., 2009) .
In centres where antibody assays are not available, and in cases where MOG antibodies have disappeared after the acute event or previously low AQP4 antibody titres have fallen below the positive cut-off, our models could be applied as a diagnostic aid. Additionally highlighting the key discriminators may give diagnostic clues as to which patients should be tested for the presence of antibodies. Probably the use of such a discriminatory model may be most helpful in classifying the cohort of seronegative NMOSD/multiple sclerosis overlap syndromes (Juryń czyk et al., 2016) , where even the experts have difficulty diagnosing and in whom the diagnosis is important for making treatment decisions. In this study we did not focus on patients with normal brain MRI, because such patients would not have been included in the definite multiple sclerosis cohort, only in the AQP4 antibody and MOG antibody groups producing a selection bias. Adding patients without brain lesions would dilute out the discriminatory brain lesion features and including normal brain MRIs would also increase the overlap between the antibody conditions (the frequency of normal brain MRIs in the two diseases were similar) and further separate them from multiple sclerosis. We excluded longitudinally extensive transverse myelitis from the classifiers as it is already recognized as a good distinguisher, and as many patients present without a history of transverse myelitis, we wished to identify further independent differentiators, which would be useful for application to diagnostically challenging patients.
MOG antibodies have been identified only in subgroups of atypical multiple sclerosis patients (Hacohen et al., 2015; Spadaro et al., 2016) and it is likely that MOG antibodies detected by optimized cell-based assays define a distinct disease process. Only one biopsy from a patient with serum MOG antibodies has been reported, and this showed type 2 immunopathological pattern on brain biopsy characterized by immunoglobulin and complement deposition. Larger pathological studies are required to assess if the features are identical to multiple sclerosis or different (Jarius et al., 2016) . Considering that multiple sclerosis and MOG antibody diseases are both associated with demyelination, it is intriguing how spontaneously distinct the multiple sclerosis and MOG antibody disease imaging features are. However, multiple sclerosis is, by definition, a chronic disease where the majority of patients become progressive whereas MOG antibody disease is monophasic in about half and relapsing rather than progressive in the others. By contrast, AQP4-antibodies are directed against astrocytes, and thus one might have hypothesized very different imaging features rather than the considerable overlap with MOG antibody images; this may represent the fact that both are antibodymediated diseases and might suggest that the target and location is not the main driver of the lesion location and characteristics. It is unclear why this overlap arises. Data on MOG expression in human brain are lacking and lesion location in AQP4 antibody NMOSD is not fully explainable by AQP4 expression. One hypothesis is that lesions may form in regions where serum antibodies enter the CNS. Another may be related to the close adjacency of myelin and astrocytes and/or their interactions.
Our study is the first one focusing on the brain imaging characteristics in MOG antibody disease and its discriminatory features, although smaller studies have noted brain lesions associated with MOG antibodies (Kitley et al., 2014; Baumann et al., 2015; Kim et al., 2015b; Prö bstel et al., 2015) . We note that poorly demarcated lesions in the brainstem or cerebellar peduncles, typically adjacent to the fourth ventricle, are also more likely in MOG antibody disease compared to multiple sclerosis. It is interesting that poorly demarcated lesions are said to be characteristic of ADEM (Poser and Brinar, 2007) and that MOG antibodies may be found presenting as ADEM, this may reflect the acute stage of the lesion and the observation that the MRI features often resolve in ADEM and other MOG antibody phenotypes (Kitley et al., 2014) rather than become chronic as in multiple sclerosis. Difficulties in building predictive models differentiating MOG antibody disease from AQP4 antibody NMOSD might be partially explained by observations that lesions previously considered to be 'NMOSD-specific', such as adjacent to the third or fourth ventricle, periaqueductal or located in area postrema (Juryń czyk et al., 2015; Kim et al., 2015a) , were present in MOG antibody patients in our study and have been also reported previously (Kitley et al., 2014) .
We separated adults from children because we noted that children typically had widespread, bilateral and large lesions, and they more often had lesions in thalamus or basal ganglia, which were very rare in adults. Interestingly, however many discriminators identified in adults also had high discriminatory value in children (e.g. Dawson's fingers, ovoid lesions adjacent to the body of lateral ventricles, T 1 hypointensities) and adults and children with the same disease typically clustered together when overviewing patients using PCA. We did not match the patients for gender as each of the three diseases is characterized by different gender distribution and we did not want to introduce selection bias. However, when labelling the patients according to gender we did not observe any gender effect. Additionally when building models with female patients only we were still able to see clear separation between multiple sclerosis and antibody-mediated conditions with the same predictors. The models were also highly predictive when built with subsets of patients selected to match for disease duration and the number of lesions was still amongst the best classifiers.
Our study limitations include the small numbers of patients, which is related to the rarity of AQP4 and MOG antibody disease and we were then limited further to those with brain lesions. We might have therefore missed small differences between the antibody-mediated conditions. The suggested discriminatory model will need further validation on future cohorts, however both internal cross-validation and independent patient set testing showed high predictive values and accurate group assignments. Adult multiple sclerosis patients were not routinely tested for AQP4-and MOG antibody as previous validation of our optimized antibody assays has demonstrated negative results in multiple sclerosis patients (Waters et al., , 2015 . We do not expect any of our adult multiple sclerosis patients had MOG antibody or AQP4 antibody disease and if they did this would bias the results in the opposite direction, i.e. to show more overlap between the multiple sclerosis and the antibody groups instead of a clear separation. We have not focused on how treatment, e.g. steroids, could affect the lesion morphology but we do not expect systematic changes as 490% scans were performed at relapse onset before treatment. Another potential limitation of this study is that the selection of imaging features is subjective, i.e. there could be additional factors that might be important differentiators. However we selected lesions according to location and characteristic and included those previously commented in multiple sclerosis and AQP4 antibody disease. The objective separation in the PCA model is a strength of this project and adds evidence to the discussion that MOG antibody disease is a distinct disease from multiple sclerosis. Finally, this work is not applicable to patients without brain lesions or to ADEM patients without NMOSD-like presentation, as these were not included in the study.
In summary, we have shown that MOG antibody disease, AQP4 antibody NMOSD and multiple sclerosis display distinct brain imaging characteristics, and that MOG antibody disease strongly separates from multiple sclerosis, supporting its distinct pathogenic nature. We have also identified in our cohort the best diagnostic classifiers, which could guide clinicians in their diagnostic and treatment decisions in seronegative NMOSD/multiple sclerosis overlap patients, aid diagnosis in centres where the antibody assays are not available or where sera was not tested at onset in low antibody titre patients. Further validation on new cohorts of these three diseases and exploration of applying this model to antibody-negative cohorts are required.
